Dr. Raghav on Adjusting Dosing With Regorafenib in CRC

In Partnership With:

Partner | Cancer Centers | <b>The University of Texas MD Anderson Cancer Center</b>

Kanwal Raghav, MBBS, MD, discusses adjusting dosing with regorafenib in patients with colorectal cancer.

Kanwal Raghav, MBBS, MD, an associate professor in the Department of Gastrointestinal Medical Oncology, of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses adjusting dosing with regorafenib (Stivarga) in patients with colorectal cancer (CRC).

For most patients, dosing criteria from the phase 2 ReDOS trial (NCT02368886), which starts with a daily oral dose of regorafenib at 80 mg and escalates by 40-mg increments each week, was utilized to achieve the drug's maximum dose of 160 mg daily, according to Raghav. While most patients will not reach the maximum-tolerated dose, some notably will, Raghav says. The point of escalating treatment, rather than starting with the highest possible dose, is because a patient who is doing well on a 120-mg dose of regorafenib will also probably be able to tolerate the 160-mg dose, Raghav says.

However, if a patient went from an 80-mg dose to 120 mg and began experiencing problems, they would not be a suitable candidate for the 160-mg dose, Raghav concludes.